These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9476977)

  • 1. Evaluation of risperidone in the neonatal 6-hydroxydopamine model of Lesch-Nyhan syndrome.
    Allen SM; Freeman JN; Davis WM
    Pharmacol Biochem Behav; 1998 Feb; 59(2):327-30. PubMed ID: 9476977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risperidone antagonism of self-mutilation in a Lesch-Nyhan patient.
    Allen SM; Rice SN
    Prog Neuropsychopharmacol Biol Psychiatry; 1996 Jul; 20(5):793-800. PubMed ID: 8870064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effect of risperidone on the self-mutilation of Lesch-Nyhan syndrome].
    Saito Y; Yamashita S; Kaneko K; Kimura S; Osawa M
    No To Hattatsu; 2001 May; 33(3):281-2. PubMed ID: 11391974
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacologic evaluation of SCH-39166, A-69024, NO-0756, and SCH-23390 in neonatal-6-OHDA-lesioned rats. Further evidence that self-mutilatory behavior induced by L-dopa is related to D1 dopamine receptors.
    Criswell HE; Mueller RA; Breese GR
    Neuropsychopharmacology; 1992 Sep; 7(2):95-103. PubMed ID: 1418306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine.
    Breese GR; Baumeister AA; McCown TJ; Emerick SG; Frye GD; Crotty K; Mueller RA
    J Pharmacol Exp Ther; 1984 Nov; 231(2):343-54. PubMed ID: 6149306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neonatal-6-hydroxydopamine treatment: model of susceptibility for self-mutilation in the Lesch-Nyhan syndrome.
    Breese GR; Baumeister AA; McCown TJ; Emerick SG; Frye GD; Mueller RA
    Pharmacol Biochem Behav; 1984 Sep; 21(3):459-61. PubMed ID: 6436840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of dopamine to serotonin in the neonatal 6-OHDA rat model of Lesch-Nyhan syndrome.
    Allen SM; Davis WM
    Behav Pharmacol; 1999 Sep; 10(5):467-74. PubMed ID: 10780253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence that D-1 dopamine receptors contribute to the supersensitive behavioral responses induced by L-dihydroxyphenylalanine in rats treated neonatally with 6-hydroxydopamine.
    Breese GR; Baumeister A; Napier TC; Frye GD; Mueller RA
    J Pharmacol Exp Ther; 1985 Nov; 235(2):287-95. PubMed ID: 3932640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurobiology of D1 dopamine receptors after neonatal-6-OHDA treatment: relevance to Lesch-Nyhan disease.
    Breese GR; Mueller RA; Napier TC; Duncan GE
    Adv Exp Med Biol; 1986; 204():197-215. PubMed ID: 2947429
    [No Abstract]   [Full Text] [Related]  

  • 10. A dopamine deficiency model of Lesch-Nyhan disease--the neonatal-6-OHDA-lesioned rat.
    Breese GR; Criswell HE; Duncan GE; Mueller RA
    Brain Res Bull; 1990 Sep; 25(3):477-84. PubMed ID: 2127238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fixed-ratio discrimination training as replacement therapy in Parkinson's disease: studies in a 6-hydroxydopamine-treated rat model.
    Van Keuren KR; Stodgell CJ; Schroeder SR; Tessel RE
    Brain Res; 1998 Jan; 780(1):56-66. PubMed ID: 9473587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-sensitization between footshock stress and apomorphine on self-injurious behavior and neostriatal catecholamines in a rat model of Lesch-Nyhan syndrome.
    Stodgell CJ; Loupe PS; Schroeder SR; Tessel RE
    Brain Res; 1998 Feb; 783(1):10-8. PubMed ID: 9479035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Use of Perinatal 6-Hydroxydopamine to Produce a Rodent Model of Lesch-Nyhan Disease.
    Knapp DJ; Breese GR
    Curr Top Behav Neurosci; 2016; 29():265-277. PubMed ID: 27029809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of L-Dopa on circadian rhythms of 6-OHDA striatal lesioned rats: a radiotelemetric study.
    Boulamery A; Simon N; Vidal J; Bruguerolle B
    Chronobiol Int; 2010 Jan; 27(2):251-64. PubMed ID: 20370468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats.
    Pinna A; Fenu S; Morelli M
    Synapse; 2001 Mar; 39(3):233-8. PubMed ID: 11284438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of purine-dopamine interactions in 6-hydroxydopamine-lesioned rats: evidence for pre- and postsynaptic influences by adenosine.
    Criswell H; Mueller RA; Breese GR
    J Pharmacol Exp Ther; 1988 Feb; 244(2):493-500. PubMed ID: 3126293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-injurious behavior and dopaminergic neuron system in neonatal 6-hydroxydopamine-lesioned rat: 2. Intracerebral microinjection of dopamine agonists and antagonists.
    Okamura H; Murakami T; Yokoyama C; Nakamura T; Ibata Y
    J Pharmacol Exp Ther; 1997 Feb; 280(2):1031-7. PubMed ID: 9023320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D1 dopamine receptor-mediated substance P depletion in the striatonigral neurons of rats subjected to neonatal dopaminergic denervation: implications for self-injurious behavior.
    Sivam SP
    Brain Res; 1989 Oct; 500(1-2):119-30. PubMed ID: 2481560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
    Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C
    Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.